A Director at BioCryst is Exercising Options

By Carrie Williams

Yesterday it was reported that a Director at BioCryst (BCRXResearch Report), George Abercrombie, exercised options to sell 74,000 BCRX shares at $2.85 a share, for a total transaction value of $1.12M.

Following George Abercrombie’s last BCRX Sell transaction on May 12, 2021, the stock climbed by 3.0%.

See today’s analyst top recommended stocks >>

Based on BioCryst’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $49.96 million and GAAP net loss of -$43,198,000. In comparison, last year the company earned revenue of $2.87 million and had a GAAP net loss of $38.61 million. The company has a one-year high of $18.48 and a one-year low of $3.30. BCRX’s market cap is $2.77 billion and the company has a P/E ratio of -12.70.

Based on 10 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $21.67, reflecting a -28.4% downside.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.